Alpha-fetoprotein-producing gastric cancer

Area of Science:

• Oncology
• Gastroenterology
• Biomarker Research

Background:

• Gastric cancer is a significant global health concern.
• Accurate prediction of liver metastasis is crucial for patient management and prognosis.
• The role of serum alpha-fetoprotein (alphaFP) in gastric cancer metastasis requires further elucidation.

Purpose of the Study:

• To measure the sero-positivity rate of alphaFP in gastric cancer patients.
• To evaluate the association between alphaFP levels and cancer progression, including liver metastasis.
• To assess the predictability of alphaFP for synchronous and metachronous liver metastasis in gastric cancer.

Main Methods:

• Enzyme-linked immunosorbent assay (ELISA) was used to measure serum alphaFP levels.
• Study included gastric cancer patients across different surgical and metastatic stages.
• Statistical analysis was performed to compare alphaFP-positive and -negative groups regarding metastasis rates and characteristics.

Main Results:

• Overall alphaFP sero-positivity rate was 9.8% (8/82), increasing with cancer progression.
• alphaFP-positive patients showed a higher rate of synchronous liver metastasis (37.5% vs. 12.2%).
• alphaFP demonstrated 75% predictability for both synchronous and metachronous liver metastasis in gastric cancer.

Conclusions:

• Serum alphaFP is a potential biomarker for predicting liver metastasis in advanced gastric cancer, particularly Stage IV.
• Elevated alphaFP levels are associated with more aggressive disease and a higher likelihood of liver involvement.
• alphaFP can aid in monitoring and predicting liver metastasis during the follow-up of gastric cancer patients.